Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
30 juin 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ascendis Pharma A/S...
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
25 juin 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zai Lab Limited (Zai Lab...
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
28 avr. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ:...
ASND INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
11 avr. 2023 18h45 HE
|
The Rosen Law Firm PA
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ascendis...
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
19 avr. 2020 16h00 HE
|
Ascendis Pharma
– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks –– Conference call today at 6 p.m. Eastern Time to...
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
28 août 2019 16h01 HE
|
Ascendis Pharma A/S
– TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials – – Global reach of endocrinology rare disease programs expands – – Conference...
Ascendis Pharma A/S Announces Participation in August Investor Conferences
29 juil. 2019 08h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
30 mai 2019 16h02 HE
|
Ascendis Pharma A/S
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
23 juil. 2018 16h44 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
26 sept. 2017 08h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...